Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia

被引：4
作者：
Widmer, N.
Gotta, V.
Haouala, A.
Decosterd, L. A.
机构：
[1] Univ Hosp Ctr, Div Clin Pharmacol & Toxicol, Lausanne, Switzerland
[2] Univ Lausanne, Lausanne, Switzerland
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 06期
关键词：
Chronic myeloid leukemia; Pharmacokinetics; Pharmacodynamics; Therapeutic drug monitoring; Prognostic factors; Imatinib; Nilotinib; GASTROINTESTINAL STROMAL TUMORS; IMATINIB PLASMA-LEVELS; POPULATION PHARMACOKINETICS; THERAPY; MECHANISMS; EFFICACY; SAFETY;
D O I：
10.1016/j.leukres.2009.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：698 / 699
页数：2
相关论文
共 23 条
[1]  
BACCARANI M, 2008, EUTOS CML WEBC CANN
[2]   Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era? [J].
Breccia, Massimo ;
Alimena, Giuliana .
LEUKEMIA RESEARCH, 2009, 33 (11) :1450-1451
[3]   Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia [J].
Clark, Richard E. .
LEUKEMIA RESEARCH, 2009, 33 (09) :1151-1155
[4]   Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [J].
Cortes, J. E. ;
Egorin, M. J. ;
Guilhot, F. ;
Molimard, M. ;
Mahon, F-X .
LEUKEMIA, 2009, 23 (09) :1537-1544
[5]   Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography [J].
Davies, Andrea ;
Hayes, Alison K. ;
Knight, Katy ;
Watmough, Sarah J. ;
Pirmohamed, Munir ;
Clark, Richard E. .
LEUKEMIA RESEARCH, 2010, 34 (06) :702-707
[6]   New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma [J].
De Francia, Silvia ;
D'Avolio, Antonio ;
De Martino, Francesca ;
Pirro, Elisa ;
Baietto, Lorena ;
Siccardi, Marco ;
Simiele, Marco ;
Racca, Silvia ;
Saglio, Giuseppe ;
Di Carlo, Francesco ;
Di Perri, Giovanni .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (18-19) :1721-1726
[7]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[8]   A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors [J].
Demetri, George D. ;
Casali, Paolo G. ;
Blay, Jean-Yves ;
von Mehren, Margaret ;
Morgan, Jeffrey A. ;
Bertulli, Rossella ;
Ray-Coquard, Isabelle ;
Cassier, Philippe ;
Davey, Monica ;
Borghaei, Hossein ;
Pink, Daniel ;
Debiec-Rychter, Maria ;
Cheung, Wing ;
Bailey, Stuart M. ;
Veronese, Maria Luisa ;
Reichardt, Annette ;
Fumagalli, Elena ;
Reichardt, Peter .
CLINICAL CANCER RESEARCH, 2009, 15 (18) :5910-5916
[9]   Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors [J].
Demetri, George D. ;
Wang, Yanfeng ;
Wehrle, Elisabeth ;
Racine, Amy ;
Nikolova, Zariana ;
Blanke, Charles D. ;
Joensuu, Heikki ;
von Mehren, Margaret .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3141-3147
[10]   Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib [J].
Gardner, Erin R. ;
Burger, Herman ;
van Schaik, Ron H. ;
van Oosterom, Allan T. ;
de Bruijn, Ernst A. ;
Guetens, Gunther ;
Prenen, Hans ;
de Jong, Floris A. ;
Baker, Sharyn D. ;
Bates, Susan E. ;
Figg, William D. ;
Verweij, Jaap ;
Sparreboom, Alex ;
Nooter, Kees .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (02) :192-201
123